SCHEDULE 13G: Commodore Capital Discloses 5.1% Stake in Nurix Therapeutics

Commodore Capital LP and Commodore Capital Master LP have jointly reported a 5.1% beneficial ownership stake in Nurix Therapeutics, Inc., holding 3,850,000 shares of common stock.

Summary

• Commodore Capital LP and Commodore Capital Master LP have filed a Schedule 13G, disclosing their beneficial ownership in Nurix Therapeutics, Inc.
• As of February 7, 2025, the reporting persons collectively beneficially own 3,850,000 shares of Nurix Therapeutics' common stock.
• This ownership represents 5.1% of the total 75,886,817 shares of common stock outstanding as of January 24, 2025, as reported in Nurix Therapeutics' Annual Report on Form 10-K.
• Commodore Capital LP acts as the investment manager to Commodore Capital Master LP.
• Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital LP and exercise investment discretion over these securities.
• The shares are held for investment purposes and not with the intent to change or influence the control of Nurix Therapeutics.

Sentiment

Score: 6

Explanation: The disclosure of a significant institutional stake is generally viewed as a positive signal, indicating investor confidence, although the filing itself is a neutral regulatory requirement.

Positives

• A significant institutional investor, Commodore Capital, has taken a 5.1% stake in Nurix Therapeutics, which could be viewed as a vote of confidence in the company's prospects.
• The investment is stated to be for passive purposes, indicating no immediate intent to disrupt company operations or management.

Negatives

• The filing itself does not contain any negative information about Nurix Therapeutics; it is a routine disclosure of ownership.

Risks

• The document does not explicitly mention risks related to Nurix Therapeutics' operations or financial health. It is a disclosure of beneficial ownership.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding Nurix Therapeutics' future performance or strategic direction. It is solely a disclosure of beneficial ownership.

Management Comments

• Michael Kramarz, Managing Partner of Commodore Capital LP, certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Nurix Therapeutics, Inc.

Industry Context

This filing indicates continued institutional investor interest in the biotechnology sector, specifically in companies like Nurix Therapeutics. Such disclosures are routine for investors crossing significant ownership thresholds and provide transparency into major shareholder positions.

Comparison to Industry Standards

• This document is a standard regulatory filing (Schedule 13G) for disclosing beneficial ownership exceeding 5%. It does not contain information that allows for a comparison of Nurix Therapeutics' operational or financial results against industry benchmarks or specific comparable companies/projects.

Stakeholder Impact

• Shareholders: The disclosure of a new significant institutional investor may positively influence investor sentiment and potentially the stock price.

Key Dates

Keywords

Nurix Therapeutics, Commodore Capital, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, Investment Manager